Reduced haloperidol in the post-mortem brains of haloperidol-treated patients.
We measured the concentrations of haloperidol and its reduced alcohol metabolite in human post-mortem tissues with high-performance/liquid chromatography using electrochemical detection. Both haloperidol and reduced haloperidol were detected and quantified in the occipital cortex of nine schizophrenic patients with a history of haloperidol treatment, but not in six samples from nontreated subjects. Reduced haloperidol concentrations were below the detection limit of the assay in several tissues of rats and mice even after 10 days of haloperidol treatment. The results suggest that reduced haloperidol is present in the brains of haloperidol-treated patients at slightly higher concentrations than haloperidol itself. Further studies are warranted to establish the possible biological importance of this haloperidol metabolite.
D000328:Adult; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D002531:Cerebellum / Q000032:analysis; D055598:Chemical Phenomena; D002621:Chemistry; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000032:analysis; D005260:Female; D006220:Haloperidol / Q000031:analogs & derivatives* / Q000032:analysis* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D008099:Liver / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009778:Occipital Lobe / Q000032:analysis; D051381:Rats; D011919:Rats, Inbred Strains; D012559:Schizophrenia / Q000188:drug therapy
C040692:4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol; C040693:1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine; D006220:Haloperidol